Lymeclin

Lymeclin is indicated for the treatment of acne, ear, nose and throat infections, acute exacerbation of chronic bronchitis, gastro-intestinal infection, urinary tract infection, non-gonococcal urethritis, trachoma, rickettsial fever, soft tissue infection.

Lymecycline is is approximately 5000 times more soluble than tetracycline base and is unique amongst tetracyclines in that it is absorbed by an active transport process across the intestinal wall, ensuring greater absorption. Lymecycline is a tetracycline derivative which blocks the access of bacterial aminoacyl-tRNA to the mRNA-ribosome complex by binding to the 30S ribosome subunit, preventing the addition of amino acids to the growing peptide chain in protein synthesis

Adults : The usual dosage for the chronic treatment of acne is 1 capsule daily: Treatment should be continued for at least 8 weeks. For other infections, the usual dosage is 1 capsule twice daily. If higher doses are required, 3-4 capsules may be given over 24 hours. Duration should be determined by the physician. Lower doses may be given for prophylaxis. Elderly : As for other tetracyclines, no specific dose adjustment is required. Children : Not recommended for children under the age of 12 years. For children over the age of 12 years the adult dosage may be given. Lymecycline capsule should always be taken with a glass of water.

The absorption of tetracyclines may be affected by the simultaneous administration of Calcium, Aluminium, Magnesium, Bismuth and Zinc salts, antacids, iron preparations and quinapril. These products should not be taken within two hours before or after taking Lymeclin. Unlike earlier tetracyclines, absorption of Lymeclin is not significantly impaired by moderate amounts of milk. An increase in the effects of anticoagulants may occur with tetracyclines. Concomitant use of diuretics should be avoided.

Hypersensitivity to lymecycline or other tetracyclines. Overt renal insufficiency. Pregnancy and lactation. Concomitant use with methoxuflurane or oral retinoids.

Care should be exercised in administering Lymeclin to patients with hepatic impairment.

Lymecycline are selectively absorbed by developing bones and teeth and may cause dental staining and enamel hypoplasia. In addition, these compounds readily cross the placental barrier and therefore Lymecycline should not be given to pregnant or lactating women.

Patient with myasthenia gravis. May exacerbate SLE. Hepatic impairment.

There is no specific treatment, but gastric lavage should be performed as soon as possible. Supportive measure should be instituted as required and a high fluid intake maintained.

Store at temperature not exceeding 30°C in a dry place. Protect from light.